Close Menu

NEW YORK (GenomeWeb) – Biocept said today that it has made a preferred provider agreement with Teneovita Medical under which the Vancouver-based provider will market and distribute Biocept's Target Selector liquid biopsy testing services to hospitals, individual oncology practices, and other cancer centers in Canada.

Additional terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.

Canadian regulators are beginning to share information from new drug studies, Undark reports.

In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.

Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.